[:es]Molecular Immunology Leads Anti-Cancer Drugs in Cuba[:]


Havana, Mar 21 .-Nearly to celebrate 25 years of founding, the Center of Molecular Immunology has today 21 new projects, including monoclonal antibodies and anti-cancer vaccines.


We are working at this time on the development of a product to treat patients with neurological diseases such as Alzheimer’s and Parkinson’s, Eduardo Ojito, director of the scientific institution, told Prensa Latina.

In a clinical trial phase, NeuroEpo, as this drug is called, is an injectable derivative of Recombinant Human Erythropoietin, with 20 years on the market to treat anemia in patients on chronic renal failure, and a leading product of this entity, he said.

According to Ojito, about 40 clinical studies are developed not only in Cuba and but also abroad, with a strong presence in Southeast Asia.

He highlighted the results of the therapeutic lung cancer vaccine CIMAvax-EGF, registered in Cuba since 2008 and in clinical trial since 2014 at the Roswell Park Institute in the United States, where more than 5,000 patients have been vaccinated.

The doctor also stated that although trials are still open, this treatment is included since 2012 in the basic medicines in the island.

Our services are present today in 31 countries around the world as a result of a network of collaborations with hospitals and universities in nations such as Switzerland, Germany, Singapore and India. (Prensa Latina)